Tushar Murthy
Northwestern University
13 Papers
4 Citations
Tushar Murthy is an academic researcher from Northwestern University. The author has contributed to research in topics: Immune system & Medicine. The author has an hindex of 4, co-authored 5 publications.
Chat about Author
Papers
Cancer-associated SF3B1 mutants recognize otherwise inaccessible cryptic 3' splice sites within RNA secondary structures.
Anil K. Kesarwani,Oscar Ramirez,Abhishek K. Gupta,Xiaodong Yang,Tushar Murthy,Alex C. Minella,Manoj M. Pillai +6 more
TL;DR: The results show that SF3B1 mutations are associated with a distinct splicing program shared across multiple clonal processes and define a biochemical mechanism for altered 3′SS choice.
77
Cyclin-dependent kinase 1 (CDK1) and CDK2 have opposing roles in regulating interactions of splicing factor 3B1 with chromatin
Tushar Murthy,Theresa Bluemn,Theresa Bluemn,Abhishek K. Gupta,Michael Reimer,Michael Reimer,Sridhar Rao,Sridhar Rao,Manoj M. Pillai,Alex C. Minella +9 more
TL;DR: It is shown that SF3B1 phosphorylation follows a dynamic pattern during cell cycle progression that depends on CDK activity, and this interaction does not seem to be related to SF3 B1's splicing function and, rather, points toward its potential role as a chromatin modifier.
12
Tolerogenic Immune-Modifying Nanoparticles Encapsulating Multiple Recombinant Pancreatic β Cell Proteins Prevent Onset and Progression of Type 1 Diabetes in Nonobese Diabetic Mice
Joseph R. Podojil,Samantha Genardi,Ming-Yi Chiang,Sandeep Kakade,Tobias Neef,Tushar Murthy,Michael T. Boyne,Adam Elhofy,Stephen D. Miller +8 more
TL;DR: Tolerance to individual epitopes/proteins fails to inhibit T1D development, and CNP treatment is both safe and induced Ag-specific tolerance in a phase 1/2a celiac disease clinical trial, suggesting Ag- specific tolerance induced by nanoparticles encapsulating multiple diabetogenic proteins is a promising approach to T1d treatment.
ONP-302 Nanoparticles Inhibit Tumor Growth By Altering Tumor-Associated Macrophages And Cancer-Associated Fibroblasts
Laxminarasimha Donthireddy,Prashanthi Vonteddu,Tushar Murthy,T. Kwak,Rukiye Eraslan,Joseph R. Podojil,Adam Elhofy,Michael T. Boyne,John J. Puisis,Filippo Veglia,Surya S. Singh,Farokh Dotiwala,Luis J. Montaner,Dmitry I. Gabrilovich +13 more
TL;DR: Data support further development of ONP-302 as a novel first-in- class anti-cancer therapeutic that can be used as a single-agent as well as in combination therapies for the treatment of solid tumors due to its ability to modulate the TME.
Biodegradable nanoparticles induce cGAS/STING-dependent reprogramming of myeloid cells to promote tumor immunotherapy
Joseph R. Podojil,Andrew C. Cogswell,Ming-Yi Chiang,Valerie Eaton,Igal Ifergan,Tobias Neef,Dan Xu,Khyati Meghani,Yanni Yu,Sophia M. Orbach,Tushar Murthy,Michael T. Boyne,Adam Elhofy,Lonnie D. Shea,Joshua J. Meeks,Stephen D. Miller +15 more
TL;DR: Findings indicate that ONP-302 allows for tumor control via reprogramming myeloid cells via activation of the STING/IL-15/NK cell mechanism, as well as increasing anti-PD-1 response rates.